Telix Doses First Patient in Phase 3 LUTEON Trial of TLX250-Tx for Renal Cancer

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/23/2026

1. GOOGL
2. TSLA
3. TXN
4. NOW
5. AMD
6. GOOG
7. INTC
8. CSX
9. KNX
10. IBM

Go back to Telix Doses First Patient in Phase 3 LUTEON Trial of TLX250-Tx for Renal Cancer
TRANS-LUX CORPORATION (NASDAQ: TLX) Delayed: 10.51 +0.19 (1.84%)
Previous Close $10.32    52 Week High $2.18 
Open $10.47    52 Week Low $0.30 
Day High $10.54    P/E N/A 
Day Low $10.40    EPS $-3.32 
Volume 120,918       

TRANS-LUX CORPORATION (NASDAQ: TLX) Delayed: 10.51 +0.19 (1.84%)
Previous Close $10.32    52 Week High $2.18 
Open $10.47    52 Week Low $0.30 
Day High $10.54    P/E N/A 
Day Low $10.40    EPS $-3.32 
Volume 120,918